| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Fresenius Medical Care (NYSE:FMS) reported quarterly earnings of $0.64 per share which beat the analyst consensus estimate of $...
Fresenius Medical Care invests EUR 312 million and successfully closes a share purchase agreement with all non-physician invest...
UBS analyst Graham Doyle downgrades Fresenius Medical Care (NYSE:FMS) from Neutral to Sell.
FDA approves Amphastar's iron sucrose injection for CKD-associated anemia, with potential for $80-100 million sales and a 2...